← Issue №20/ week of Nov 15, 2026/Colorectal

Colonoscopy outcomes after positive multi-target stool DNA testing in patients with and without a prior normal colonoscopy: Data from the New Hampshire Colonoscopy Registry.

From GI Signals issue №20: what this paper found, what it changes, and where it sits against the current standard of care, reviewed by Simon Mathews, MD.

Colorectal retrospective · n=1,733 · Nov 13, 2026 · Clin Transl Gastro · IF 3.4

Colonoscopy outcomes after positive multi-target stool DNA testing in patients with and without a prior normal colonoscopy: Data from the New Hampshire Colonoscopy Registry.

New evidencecolorectal cancer screeningbiomarkerepidemiology
What it foundPatients with a prior normal colonoscopy had 19.1% prevalence of advanced colorectal neoplasia after a positive mt-sDNA test, half the odds of advanced findings compared to those without prior colonoscopy (OR 0.51; 95% CI 0.41-0.62).
ContextThis literature reports that the yield of advanced neoplasia following a positive multi-target stool DNA test in patients with a prior normal colonoscopy remains an area of investigation.
Measured against the standard of care· USMSTF 2017 (Rex et al., Gastroenterology) + USMSTF 2022 focused update on age (Patel et al., Gastroenterology 2022;162:285-299) / ACS 2026 (CA Cancer J Clin)

… Tier 2 alternatives are multi-target stool DNA every 3 years, CT colonography every 5 years, and flexible sigmoidoscopy every 5-10 years. … ACS says a positive stool or blood test should be followed by colonoscopy, preferably within 6 months. The 2026 ASGE paper on follow-up after an abnormal stool test is an implementation review (navigation, tracking, direct-access colonoscopy), not a new screening guideline.

From our summary of this standard, unedited — the part the paper bears on. … marks omitted text. Our wording, not the guideline's; read the source for its own text.

Our full summary of this standard

U.S. Multi-Society Task Force (2017 guideline, revised by the 2022 focused update on age to start and stop): offer average-risk colorectal cancer screening to everyone aged 45-75. Screening at 45-49 is a weaker recommendation than at 50-75. Colonoscopy every 10 years and annual FIT are the Tier 1 cornerstones. Tier 2 alternatives are multi-target stool DNA every 3 years, CT colonography every 5 years, and flexible sigmoidoscopy every 5-10 years. Capsule colonoscopy every 5 years is Tier 3. Any abnormal non-colonoscopy test requires a diagnostic colonoscopy, and a stool test should not be offered to a patient who would decline follow-up colonoscopy. Patients who are up to date with negative prior screening, particularly a high-quality colonoscopy, may consider stopping at 75 or when life expectancy is under 10 years. Decisions at 76-85 are individualized by health and prior screening, and screening after 85 is not recommended. The American Cancer Society's May 2026 guideline agrees on the 45-75 range, no screening after 85, and colonoscopy as the preferred option. It adds the next-generation mt-sDNA test and the multitarget stool RNA test (ColoSense), both every 3 years, and it adds an FDA-approved blood-based cfDNA test (Shield) only for people who decline or do not complete visual or stool screening. ACS says a positive stool or blood test should be followed by colonoscopy, preferably within 6 months. The 2026 ASGE paper on follow-up after an abnormal stool test is an implementation review (navigation, tracking, direct-access colonoscopy), not a new screening guideline.

USMSTF 2017 (Rex et al., Gastroenterology) + USMSTF 2022 focused update on age (Patel et al., Gastroenterology 2022;162:285-299) / ACS 2026 (CA Cancer J Clin) · reviewed 2026-10-11 ↗
Anderson JC … Butterly LF · Clinical and Translational Gastroenterology · IF 3.4 · PubMed ↗Permalink
← Read the whole of issue №20 Every paper GI Signals surfaces gets a page like this one. All issues